Division of Nephrology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York
Division of Nephrology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.
J Am Soc Nephrol. 2020 Sep;31(9):2145-2157. doi: 10.1681/ASN.2020040509. Epub 2020 Jul 15.
Reports from centers treating patients with coronavirus disease 2019 (COVID-19) have noted that such patients frequently develop AKI. However, there have been no direct comparisons of AKI in hospitalized patients with and without COVID-19 that would reveal whether there are aspects of AKI risk, course, and outcomes unique to this infection.
In a retrospective observational study, we evaluated AKI incidence, risk factors, and outcomes for 3345 adults with COVID-19 and 1265 without COVID-19 who were hospitalized in a large New York City health system and compared them with a historical cohort of 9859 individuals hospitalized a year earlier in the same health system. We also developed a model to identify predictors of stage 2 or 3 AKI in our COVID-19.
We found higher AKI incidence among patients with COVID-19 compared with the historical cohort (56.9% versus 25.1%, respectively). Patients with AKI and COVID-19 were more likely than those without COVID-19 to require RRT and were less likely to recover kidney function. Development of AKI was significantly associated with male sex, Black race, and older age (>50 years). Male sex and age >50 years associated with the composite outcome of RRT or mortality, regardless of COVID-19 status. Factors that were predictive of stage 2 or 3 AKI included initial respiratory rate, white blood cell count, neutrophil/lymphocyte ratio, and lactate dehydrogenase level.
Patients hospitalized with COVID-19 had a higher incidence of severe AKI compared with controls. Vital signs at admission and laboratory data may be useful for risk stratification to predict severe AKI. Although male sex, Black race, and older age associated with development of AKI, these associations were not unique to COVID-19.
治疗 2019 冠状病毒病(COVID-19)患者的中心报告指出,此类患者常发生急性肾损伤(AKI)。然而,目前尚无 COVID-19 住院患者与非 COVID-19 住院患者 AKI 的直接比较,无法揭示该感染是否存在 AKI 风险、病程和结局方面的独特之处。
在一项回顾性观察性研究中,我们评估了在纽约市一个大型医疗系统住院的 3345 名 COVID-19 患者和 1265 名无 COVID-19 的成年人的 AKI 发生率、危险因素和结局,并与同一医疗系统一年前住院的 9859 名个体的历史队列进行了比较。我们还开发了一个模型来识别 COVID-19 患者发生 2 期或 3 期 AKI 的预测因素。
与历史队列相比,COVID-19 患者的 AKI 发生率更高(分别为 56.9%和 25.1%)。发生 AKI 的 COVID-19 患者比未发生 COVID-19 的患者更有可能需要肾脏替代治疗,且恢复肾功能的可能性更小。AKI 的发生与男性、黑种人和年龄>50 岁显著相关。无论 COVID-19 状态如何,男性和年龄>50 岁均与肾脏替代治疗或死亡率的复合结局相关。预测 2 期或 3 期 AKI 的因素包括初始呼吸频率、白细胞计数、中性粒细胞/淋巴细胞比值和乳酸脱氢酶水平。
与对照组相比,因 COVID-19 住院的患者发生严重 AKI 的发生率更高。入院时的生命体征和实验室数据可能有助于进行风险分层,以预测严重 AKI。尽管男性、黑种人和年龄>50 岁与 AKI 的发生相关,但这些关联并非 COVID-19 所特有。